Buserelin may induce early, transient increase in serum testosterone or estradiol which can lead in the exacerbation of signs and symptoms of metastatic prostate cancer or endometriosis. Adverse reactions reported at more than 10% occurrence include headache, loss of libido in patients with prostate cancer, hot flashes, hypermenorrhea, decreased libido in prostate cancer and endometriosis, flatulence, impotence, vaginal dryness, back pain and nasal mucosa irritation.
Buserelin is a synthetic peptide analog of the luteinizing hormone-releasing hormone (LHRH) agonist, which stimulates the pituitary gland's gonadotrophin-releasing hormone receptor (GnRHR). It is used in prostate cancer treatment.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Corifollitropin alfa | The therapeutic efficacy of Corifollitropin alfa can be increased when used in combination with Buserelin. |
| Choline C 11 | Buserelin may decrease effectiveness of Choline C 11 as a diagnostic agent. |
| Capromab pendetide | Buserelin may decrease effectiveness of Capromab pendetide as a diagnostic agent. |
| Insulin human | The therapeutic efficacy of Insulin human can be decreased when used in combination with Buserelin. |
| Insulin lispro | The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Buserelin. |
| Insulin glargine | The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Buserelin. |
| Insulin pork | The therapeutic efficacy of Insulin pork can be decreased when used in combination with Buserelin. |
| Troglitazone | The therapeutic efficacy of Troglitazone can be decreased when used in combination with Buserelin. |
| Glimepiride | The therapeutic efficacy of Glimepiride can be decreased when used in combination with Buserelin. |
| Acarbose | The therapeutic efficacy of Acarbose can be decreased when used in combination with Buserelin. |
| Sulfadiazine | The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Buserelin. |
| Rosiglitazone | The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Buserelin. |
| Acetohexamide | The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Buserelin. |
| Miglitol | The therapeutic efficacy of Miglitol can be decreased when used in combination with Buserelin. |
| Chlorpropamide | The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Buserelin. |
| Nateglinide | The therapeutic efficacy of Nateglinide can be decreased when used in combination with Buserelin. |
| Tolazamide | The therapeutic efficacy of Tolazamide can be decreased when used in combination with Buserelin. |
| Repaglinide | The therapeutic efficacy of Repaglinide can be decreased when used in combination with Buserelin. |
| Phenformin | The therapeutic efficacy of Phenformin can be decreased when used in combination with Buserelin. |
| Sulfamethoxazole | The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Buserelin. |
| Glyburide | The therapeutic efficacy of Glyburide can be decreased when used in combination with Buserelin. |
| Glipizide | The therapeutic efficacy of Glipizide can be decreased when used in combination with Buserelin. |
| Gliclazide | The therapeutic efficacy of Gliclazide can be decreased when used in combination with Buserelin. |
| Tolbutamide | The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Buserelin. |
| Pioglitazone | The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Buserelin. |
| Bromocriptine | The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Buserelin. |
| Gliquidone | The therapeutic efficacy of Gliquidone can be decreased when used in combination with Buserelin. |
| Mitiglinide | The therapeutic efficacy of Mitiglinide can be decreased when used in combination with Buserelin. |
| Sitagliptin | The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Buserelin. |
| Sunitinib | The therapeutic efficacy of Sunitinib can be decreased when used in combination with Buserelin. |
| Exenatide | The therapeutic efficacy of Exenatide can be decreased when used in combination with Buserelin. |
| Mecasermin | The therapeutic efficacy of Mecasermin can be decreased when used in combination with Buserelin. |
| Pramlintide | The therapeutic efficacy of Pramlintide can be decreased when used in combination with Buserelin. |
| Glisoxepide | The therapeutic efficacy of Glisoxepide can be decreased when used in combination with Buserelin. |
| Insulin aspart | The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Buserelin. |
| Insulin detemir | The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Buserelin. |
| Insulin glulisine | The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Buserelin. |
| Glymidine | The therapeutic efficacy of Glymidine can be decreased when used in combination with Buserelin. |
| AICA ribonucleotide | The therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Buserelin. |
| Buformin | The therapeutic efficacy of Buformin can be decreased when used in combination with Buserelin. |
| Vildagliptin | The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Buserelin. |
| Voglibose | The therapeutic efficacy of Voglibose can be decreased when used in combination with Buserelin. |
| NN344 | The therapeutic efficacy of NN344 can be decreased when used in combination with Buserelin. |
| AMG-222 | The therapeutic efficacy of AMG-222 can be decreased when used in combination with Buserelin. |
| Bisegliptin | The therapeutic efficacy of Bisegliptin can be decreased when used in combination with Buserelin. |
| Alogliptin | The therapeutic efficacy of Alogliptin can be decreased when used in combination with Buserelin. |
| Dapagliflozin | The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Buserelin. |
| Saxagliptin | The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Buserelin. |
| Liraglutide | The therapeutic efficacy of Liraglutide can be decreased when used in combination with Buserelin. |
| Gosogliptin | The therapeutic efficacy of Gosogliptin can be decreased when used in combination with Buserelin. |
| Linagliptin | The therapeutic efficacy of Linagliptin can be decreased when used in combination with Buserelin. |
| Canagliflozin | The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Buserelin. |
| Glibornuride | The therapeutic efficacy of Glibornuride can be decreased when used in combination with Buserelin. |
| Benfluorex | The therapeutic efficacy of Benfluorex can be decreased when used in combination with Buserelin. |
| Empagliflozin | The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Buserelin. |
| Albiglutide | The therapeutic efficacy of Albiglutide can be decreased when used in combination with Buserelin. |
| Dulaglutide | The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Buserelin. |
| Lobeglitazone | The therapeutic efficacy of Lobeglitazone can be decreased when used in combination with Buserelin. |
| Netoglitazone | The therapeutic efficacy of Netoglitazone can be decreased when used in combination with Buserelin. |
| Rivoglitazone | The therapeutic efficacy of Rivoglitazone can be decreased when used in combination with Buserelin. |
| Ciglitazone | The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Buserelin. |
| Lixisenatide | The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Buserelin. |
| Insulin beef | The therapeutic efficacy of Insulin beef can be decreased when used in combination with Buserelin. |
| Insulin degludec | The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Buserelin. |
| Insulin peglispro | The therapeutic efficacy of Insulin peglispro can be decreased when used in combination with Buserelin. |
| Insulin tregopil | The therapeutic efficacy of Insulin tregopil can be decreased when used in combination with Buserelin. |
| Ipragliflozin | The therapeutic efficacy of Ipragliflozin can be decreased when used in combination with Buserelin. |
| Dutogliptin | The therapeutic efficacy of Dutogliptin can be decreased when used in combination with Buserelin. |
| Allicin | The therapeutic efficacy of Allicin can be decreased when used in combination with Buserelin. |
| Tofogliflozin | The therapeutic efficacy of Tofogliflozin can be decreased when used in combination with Buserelin. |
| Ertugliflozin | The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Buserelin. |
| 2,4-thiazolidinedione | The therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Buserelin. |
| Teneligliptin | The therapeutic efficacy of Teneligliptin can be decreased when used in combination with Buserelin. |
| Omarigliptin | The therapeutic efficacy of Omarigliptin can be decreased when used in combination with Buserelin. |
| Carmegliptin | The therapeutic efficacy of Carmegliptin can be decreased when used in combination with Buserelin. |
| Gemigliptin | The therapeutic efficacy of Gemigliptin can be decreased when used in combination with Buserelin. |
| Anagliptin | The therapeutic efficacy of Anagliptin can be decreased when used in combination with Buserelin. |
| Evogliptin | The therapeutic efficacy of Evogliptin can be decreased when used in combination with Buserelin. |
| Sotagliflozin | The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Buserelin. |
| Balaglitazone | The therapeutic efficacy of Balaglitazone can be decreased when used in combination with Buserelin. |
| Remogliflozin etabonate | The therapeutic efficacy of Remogliflozin etabonate can be decreased when used in combination with Buserelin. |
| Carbutamide | The therapeutic efficacy of Carbutamide can be decreased when used in combination with Buserelin. |
| Guar gum | The therapeutic efficacy of Guar gum can be decreased when used in combination with Buserelin. |
| Metahexamide | The therapeutic efficacy of Metahexamide can be decreased when used in combination with Buserelin. |
| Semaglutide | The therapeutic efficacy of Semaglutide can be decreased when used in combination with Buserelin. |
| Taspoglutide | The therapeutic efficacy of Taspoglutide can be decreased when used in combination with Buserelin. |
| Englitazone | The therapeutic efficacy of Englitazone can be decreased when used in combination with Buserelin. |
| Tirzepatide | The therapeutic efficacy of Tirzepatide can be decreased when used in combination with Buserelin. |
| Gastric inhibitory polypeptide | The therapeutic efficacy of Gastric inhibitory polypeptide can be decreased when used in combination with Buserelin. |
| Leuprolide | The risk or severity of QTc prolongation can be increased when Buserelin is combined with Leuprolide. |
| Goserelin | The risk or severity of QTc prolongation can be increased when Buserelin is combined with Goserelin. |
| Erythromycin | The risk or severity of QTc prolongation can be increased when Buserelin is combined with Erythromycin. |
| Azithromycin | The risk or severity of QTc prolongation can be increased when Buserelin is combined with Azithromycin. |
| Moxifloxacin | The risk or severity of QTc prolongation can be increased when Buserelin is combined with Moxifloxacin. |
| Ranolazine | The risk or severity of QTc prolongation can be increased when Buserelin is combined with Ranolazine. |
| Sulfisoxazole | The therapeutic efficacy of Sulfisoxazole can be decreased when used in combination with Buserelin. |
| Amitriptyline | The risk or severity of QTc prolongation can be increased when Buserelin is combined with Amitriptyline. |
| Methadone | The risk or severity of QTc prolongation can be increased when Buserelin is combined with Methadone. |
| Diltiazem | The risk or severity of QTc prolongation can be increased when Buserelin is combined with Diltiazem. |
| Clozapine | The risk or severity of QTc prolongation can be increased when Buserelin is combined with Clozapine. |